© Reuters. FILE PHOTO: A sign marks a Biogen facility in Boston, U.S., March 9, 2020. REUTERS/Brian Snyder
By Deena Beasley and Leroy Leo
(Reuters) -The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer’s treatments including Biogen Inc (NASDAQ:)’s Aduhelm but will require patients to be enrolled in a clinical trial, limiting access to the treatment more than many expected.
Biogen shares were down 7.3% at $224 in extended trading on Tuesday. Shares of Biogen’s Japanese partner Eisai Co (OTC:) Ltd slid 2.6% in Tokyo.
The decision from the U.S. Centers for Medicare and Medicaid Services (CMS), the health agency that runs Medicare, could change as it seeks comment from companies and patients. A final decision is due on April 11.
The final CMS coverage terms are expected to…